Wellbutrin Offers Optimistic Case Study For Tysabri

The regulatory and commercial history of the antidepressant brand Wellbutrin may be one precedent for Biogen Idec and Elan to emulate in attempting to salvage the multiple sclerosis therapy Tysabri

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet